SCHEMBL20102404

SCHEMBL20102404

CCCc1cc2c(c(F)c1F)-c1c-2ccc(OCC)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
GABRA1 P14867 3/20 0.37
GABRB2 P47870 3/20 0.37
FGFR2 P21802 2/20 0.36
HMGCR P04035 1/20 0.35
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
KDM1A O60341 2/20 0.32
GAA P10253 2/20 0.32
MAPT P10636 2/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
FGFR1 P11362 1/20 0.32
ATM Q13315 1/20 0.31
CALM1 P0DP23 1/20 0.31
ALOX5AP P20292 1/20 0.30
FEN1 P39748 1/20 0.30
F2RL1 P55085 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20102405 0.90 FGFR2 (0.34) CTSLCTSSCTSKFGFR2PTGS2
SCHEMBL20102406 0.87 THRB (0.37) CTSLCTSSCTSKGAAMAPT
SCHEMBL20102470 0.85 FGFR2 (0.33) CTSLCTSSCTSKFGFR2
SCHEMBL20111337 0.84 GABRA1 (0.33) CTSLCTSSCTSKGABRA1GABRB2
SCHEMBL20111248 0.82 QRFPR (0.36) KDM1AMAPTALDH1A1
SCHEMBL20102468 0.81 HPGD (0.30) KDM1A
SCHEMBL20117586 0.80 ALDH1A1 (0.32) FGFR2KDM1AALDH1A1
SCHEMBL20111478 0.80 HPGD (0.34) CTSLCTSSCTSK
SCHEMBL20102414 0.80 FGFR2 (0.39) FGFR2PTGS1PTGS2KDM1AGAA
SCHEMBL12579513 0.80 CTSS (0.56) CTSLCTSSCTSKGABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2019-06-18 US disclosed
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-05-03 US disclosed
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE YBX1, PIEZO1, C1S CTSL 2729/4885CTSS 2436/4885CTSK 2311/4885
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device YBX1, PIEZO1, C1S CTSL 2729/4885CTSS 2436/4885CTSK 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.